Funding for this research was provided by:
Vestre Viken Hospitsl Trust
Oslo University Hospital
The Norwegian Cancer Society
Vestre Viken Hospital Trust
Article History
Received: 5 August 2022
Accepted: 5 October 2022
First Online: 14 October 2022
Declarations
:
: The authors declare no conflicts of interest.
: Informed consent was obtained from all individual participants included in the study.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The SECA 1 and 2 studies were open prospective studies approved by the ethical board and registered at ClinicalTrials.gov with registration number NCT01311453 for the SECA-1 and NCT01479608 for the SECA-2 study.